Ann: Leadership Changes and Strategic Review, page-5

Yes, DR has in the past been the face of BNO and has spruiked  the endless opportunities for BNO on the world stage. Turned out, she was merely an actor with not much to perform about. I can’t believe that so much emphasis was put on one BNC... surely the company should have been aware of the effects of the drug before it was put up for the test ?  DR certainly has received an awful lot more financial return over many years than the loyal shareholders.  I haven’t even bothered to see how many BNO shares she either held or was entitled to.  BNO has been like a funnel with endless compounds to start with, funnelling down to almost one,..... and for that matter do we have anything at all to show for all the years of testing, initially with the potential cancer stopping drug and others, all the way down to a compound for anxiety that doesn’t pass the test ?  It will be interesting to see where DR ends up......... probably less financially stressed than the shareholders she left behind !